Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 10/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22448584 | 0.81 | PGK1 (0.41) | P2RX3P2RX2PDE10APOLBGAA | |
| SCHEMBL7858396 | 0.80 | PDE10A (0.46) | P2RX3P2RX2PDE10APOLBGAA | |
| SCHEMBL22448659 | 0.80 | NLRP3 (0.38) | P2RX3P2RX2PDE10AAAK1 | |
| SCHEMBL22439469 | 0.78 | P2RX3 (0.57) | P2RX3P2RX2 | |
| SCHEMBL29839596 | 0.78 | P2RX3 (0.57) | P2RX3P2RX2 | |
| SCHEMBL22448666 | 0.76 | P2RX3 (0.42) | P2RX3P2RX2POLBGAAGFER | |
| SCHEMBL22448809 | 0.74 | CYP1A2 (0.47) | P2RX3P2RX2 | |
| SCHEMBL22350126 | 0.70 | P2RX3 (0.45) | P2RX3P2RX2POLBGAAGFER | |
| SCHEMBL7858376 | 0.70 | PDGFRB (0.47) | P2RX3P2RX2PDE10A | |
| SCHEMBL30215766 | 0.68 | P2RX3 (0.85) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3712144-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885PDE10A 307/4885 |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885PDE10A 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.